Medico Reach

SEPTEMBER 12, 2022

billion by 2030. Upon immediately subjecting the patient to an X-ray, the barium appears white as doctors observe how it outlines the digestive tract. . Option to treat the patient during endoscopy. But since the patient is already sedated while performing the procedure, the doctor can treat the problem during endoscopy.

Marketing 52

Marketing Doctors Training Medical 52

European Pharmaceutical Review

FEBRUARY 2, 2024

So construction of the new radioligand therapy manufacturing site in France is a major step towards making these promising new treatments available to cancer patients with high unmet needs. The build of ATLab Valenciennes has been selected under the France 2030 plan. As a result, the project will receive public support of almost €3.8

Manufacturing 87

Manufacturing Distribution Leads Pharmaceutical 87

PM360

SEPTEMBER 28, 2022

One fast-growing group in particular that requires a patient-centric and culturally relevant approach to marketing is the Hispanic audience, which is extremely diverse. The patient landscape continues to evolve. Projections show that by 2030, the population will feature a 50% racial and ethnic majority. Evolving Demographics.

Patients 98

Patients Marketing Doctors Healthcare 98

Pharmaceutical Technology

SEPTEMBER 22, 2022

It is the year 2030. Remote patient monitoring technology, such as smartwatches, and smart devices for your home, such as smart toilets, will detect indicators of disease, also known as biomarkers. With the personalised medicine market reaching $93bn by 2030, there will be a range of treatments available. It is the year 2030.

Healthcare 137

Healthcare Healthcare Electronics Healthcare Provider 137

PharmaTimes

JANUARY 6, 2023

Collaboration will focus on providing up to 10,000 patients with personalised mRNA by 2030

Government 85

Government Patients 85

European Pharmaceutical Review

MAY 2, 2024

As a result, the market is expected to reach $719 billion by 2030, 1 Sigma Mostafa, PhD, Chief Scientific Officer at KBI Biopharma shared with EPR. It is encouraging to see even large pharma widening their portfolio with a range of new modalities that are expected to have higher efficacy or better performance in targeted patient groups.

Medicine 99

Medicine Manufacturing Biopharma Engineering 99

European Pharmaceutical Review

MARCH 14, 2023

Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining Seagen’s antibody -drug conjugate (ADC) technology… with Pfizer’s capabilities and expertise,” shared Dr Albert Bourla, Pfizer Chairman and Chief Executive Officer. “The billion of revenue in 2023.

Food and Drug Administration 108

Food and Drug Administration Medicine Engineering Food 108

World of DTC Marketing

MAY 16, 2022

Will patients, who are obese and don’t have Type 2 diabetes, ask for the drug for weight loss, and will patients understand the risks? Mounjaro, Lilly’s new diabetes drug, is sure to be in high demand initially after launch, but patients should be aware of its side effects. A matter of trust?

Food and Drug Administration 218

Food and Drug Administration Side effects Pharma Prescription 218

PharmaTech

OCTOBER 22, 2023

According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030. With pharma having discovered the pitfalls of individual solutions, many are building a new clinical trial technology foundation that can better scale according to their needs.

Pharma 52

Pharma Marketing Patients 52

Clarivate

AUGUST 17, 2022

In our latest podcast, Ideas to Innovation, we speak with Dr. Grace Lomax, the clinical director at Patient Connect, part of Clarivate. Also listed as a target is reducing premature deaths from non-communicable diseases by one third by 2030. Supporting patients at the point of care. Dr. Grace Lomax.

Healthcare 52

Healthcare Healthcare Patients Physicians 52

European Pharmaceutical Review

JANUARY 22, 2024

million by 2030, according to a report by ResearchAndMarkets. Between 2023 to 2030, this represents a CAGR of 15.13 Crititically, they also enable a lower cross-contamination risk, enhancing patient safety. The global extractable and leachable (E&L) testing services market is projected to value $2.57

Marketing 52

Marketing Safety Medicine Pharmaceutical 52

European Pharmaceutical Review

SEPTEMBER 12, 2023

Data predicted that in 2030, more than half of US Food and Drug Administration (FDA)-approved drugs will involve AI in their development and/or manufacturing. Looking further ahead, by 2030, over half (52 percent) of new drugs approved will be discovered or developed using AI.

Food and Drug Administration 98

Food and Drug Administration Manufacturing FDA Pharmaceutical 98

European Pharmaceutical Review

JULY 6, 2023

BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. The partnership will provide cancer patients with improved access to the latest cancer trials and therapies currently being developed.

Government 91

Government Patients Pharmaceutical 91

Pharmaceutical Technology

APRIL 18, 2023

It dissolves rapidly releasing the active ingredient in the mouth, meaning there is no requirement for the patient to swallow a pill. This route of administration makes it a potential alternative, especially for migraine patients who suffer from migraine-related nausea.

Food and Drug Administration 98

Food and Drug Administration FDA Food Manufacturing 98

World of DTC Marketing

JULY 17, 2022

A Harvard study found that almost half of Americans are expected to be obese by 2030, accounting for up to 18 percent of healthcare spending on related conditions, ranging from heart disease and stroke to osteoarthritis. . It has to persuade patients to sign up for some heinous side effects. Then there is the price.

Side effects 209

Side effects Insurance Doctors Prescription 209

World of DTC Marketing

AUGUST 22, 2022

The costs associated with direct cancer care are staggering for patients and their families. In 2018 cancer patients in the U.S. on cancer-related health care in 2015, and this amount is projected to grow to $246 billion by 2030—an increase of 34%. Cancer also represents a significant portion of total U.S. health care spending.

Food 229

Food Education Government Patients 229

Pharmaceutical Technology

MAY 19, 2023

While MS is not a terminal diagnosis, the effect of the disease on the CNS can significantly impact patients’ independence and disturb their daily lives. Key opinion leaders (KOLs) interviewed by GlobalData emphasised that the high cost of DMTs for MS can have a major impact on patients, their families, and society.

Prospecting 98

Prospecting Marketing Patients Leads 98

Pharmaceutical Technology

OCTOBER 4, 2022

Treatments to enhance the lives of debilitating neurological and neuropsychiatric disease patients are part of Biohaven’s portfolio. The success of NURTEC ODT coupled with Biohaven’s CGRP pipeline will strengthen Pfizer’s innovative Internal Medicine pipeline through 2030 and beyond. .

Biopharma 106

Biopharma Food and Drug Administration Medicine FDA 106

PharmaTech

OCTOBER 22, 2023

According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030. As technology advances and the need for more efficient and patient-centric approaches to clinical trials grows, DCTs have emerged as a powerful solution.

Electronics 40

Electronics Recruitment Healthcare Healthcare 40

European Pharmaceutical Review

JANUARY 6, 2023

BioNTech has signed an agreement with the UK Government to help accelerate clinical trials for personalised mRNA immunotherapies, with the aim to provide personalised cancer therapies for up to 10,000 patients by the end of 2030. Infectious disease vaccines. Expansion of BioNTech’s UK footprint.

Government 52

Government Recruitment Patients Networking 52

Celeritas

SEPTEMBER 26, 2022

The QR code payment market is projected to rise to $35 billion by 2030. A) Aiding Healthcare Professionals (HCPs): Storage of Patient Information: The common method of use of QR codes is in the organization and accessibility of patient records. In essence, patients’ files are all synced to a medical database.

Physicians 52

Physicians Patients Medical Management 52

European Pharmaceutical Review

FEBRUARY 8, 2023

The number of blood cancer patients receiving CD19-directed CAR-T therapies is set to boom over the next decade from approximately 3,700 patients in 2021 to nearly 13,500 patients in 2031. This allows for a large total eligible patient population despite capturing less patient share relative to other CD19 CAR-T agents.

Marketing 95

Marketing Sales Physicians Patients 95

Pharmaceutical Technology

JUNE 7, 2023

of patients’ body weight (52lb or 24kg) and greater than 50% of patients taking Mounjaro achieving at least 20% body weight reductions. In addition, Mounjaro is estimated to gain sales of around $20bn by 2030 and become the leading GLP-1 in the obesity market, as well as in T2D.

Leads 98

Leads Marketing FDA Sales 98

Pharma Leaders

JUNE 16, 2023

Generic and biosimilar medicines provider Sandoz has introduced a global action plan to provide patients with quick access to biologic medicines. Dubbed Act4Biosimilars Action Plan, the new roadmap has been designed to boost the adoption of global biosimilar products by at least 30% points in more than 30 countries by 2030.

Medicine 52

Medicine Patients Healthcare Healthcare 52

European Pharmaceutical Review

SEPTEMBER 15, 2023

In the Dercum’s disease patients who received the high-dose, 64.5 percent, the global market of Dercum’s disease treatment in 2030 is predicted to grow to $19.95 For the secondary endpoints, 90.3 percent of painful lipomas in the high-dose group showed dimensions reduction after CBL-514 treatments when compared to baseline.

Safety 118

Safety Marketing Medicine Pharmaceutical 118

Pharmaceutical Technology

MARCH 24, 2023

This will allow Takeda to serve more patients in the country sustainably. Slated to commence operations by 2030, the new site will add incremental capacity to the company’s global manufacturing network.

Manufacturing 52

Manufacturing Networking Patients Pharma 52

World of DTC Marketing

NOVEMBER 3, 2020

A prestigious team of medical scientists has projected that by 2030, nearly one in two adults will be obese, and nearly one in four will be severely obese. Our healthcare system is set up to treat patients not to prevent bad health habits. There are many reasons why Americans are so unhealthy, including socioeconomic circumstances.

Insurance 190

Insurance Healthcare Healthcare Physicians 190

European Pharmaceutical Review

JANUARY 27, 2023

.” “Efforts to expand access to medicines, especially insulin, are only beneficial when effective cold chain systems are in place to keep them at the right temperature on their way to patients,” commented Leigh Ann Pusey, Executive Vice President of corporate affairs and communications for Lilly.

Distribution 88

Distribution Transportation Medicine Medical 88

European Pharmaceutical Review

OCTOBER 12, 2022

A Phase III trial evaluating TauRx Therapeutics’ oral drug hydromethylthionine mesylate (HMTM), a tau aggression inhibitor, showed the medication continued to improve cognition over a pre-treatment baseline in patients with early Alzheimer’s for the first time. The safety data from the trial was consistent with earlier trial data.

Side effects 90

Side effects Safety Patients Sales 90

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. ” Image via @BioNTech_Group twitter.

Manufacturing 106

Manufacturing Patients Leads 106

Pharmaceutical Technology

FEBRUARY 10, 2023

4DMT had paused enrollment of patients to two of its trials for 4D-310 last month following a significant adverse event where three patients experienced kidney issues; however, these were treated and resolved in a four-week period.

FDA 105

FDA Competition Leads Marketing 105

pharmaphorum

JULY 27, 2022

The new system – called DTx Connect – aims to help physicians order both prescription and non-prescription DTx and diagnostics through a simple interface, and monitor shipping and delivery to their patients. It works like this. billion in 2021. The post AmerisourceBergen aims to make digital therapeutics access easier appeared first on.

Electronics 70

Electronics Physicians Prescription Doctors 70

Pharmaceutical Technology

MAY 9, 2023

INBRIJA is currently indicated in the US for use in the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult Parkinson’s disease (PD) patients who received a levodopa/dopa-decarboxylase inhibitor. The firm will also receive a fixed fee for each INBRIJA carton provided to Chance.

Distribution 52

Distribution Medical Pharmaceutical Sales 52

Pharmaceutical Technology

APRIL 19, 2023

Telehealth is on the rise , with its market expected to be worth $3.8bn by 2030, according to GlobalData. Companies are moving to provide telehealth services to patients to cater to attitudes, which are shifted during the Covid-19 pandemic, and persist today.

Food and Drug Administration 52

Food and Drug Administration Food FDA Healthcare 52

Pharmaceutical Technology

JULY 15, 2022

Yet, data transparency must be foregrounded to foster patient trust, or AI’s potential in fertility treatments will not be realised. This has the potential to increase the accessibility of IVF if companies pass on reductions in running costs to patients. Doing so will be vital in slowing the pace at which populations are ageing.

Medical 105

Medical Prospecting Education Patients 105

Medico Reach

MARCH 24, 2023

Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. To address the shortcomings of existing treatments, routine utilization of patient data becomes crucial. It is further expected to reach USD 14,505 million in 2030. billion by 2030. billion in 2021.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. To address the shortcomings of existing treatments, routine utilization of patient data becomes crucial. It is further expected to reach USD 14,505 million in 2030. billion by 2030. billion in 2021.

Marketing 52

Marketing Medicine Healthcare Healthcare 52